CoChat
Sign Up
Cited by 48Inflammatory Bowel DiseaseInflammatory mediators and NSAID effectsGastrointestinal motility and disorders

The arachidonic acid metabolite 11β-ProstaglandinF2α controls intestinal epithelial healing: deficiency in patients with Crohn’s disease

Open access
Coquenlorge, Sabrina, Van Landeghem, Laurianne, Jaulin, Julie, Cenac, Nicolas, Vergnolle, Nathalie, Duchalais, Emilie, Neunlist, Michel, Rolli-Derkinderen, Malvyne·2016·Scientific Reports
DOI 10.1038/srep25203PMC PMC4853710
Open this paper in CoChat — free accountOpen PDF

Abstract

In healthy gut enteric glial cells (EGC) are essential to intestinal epithelial barrier (IEB) functions. In Crohn’s Disease (CD), both EGC phenotype and IEB functions are altered, but putative involvement of EGC in CD pathogenesis remains unknown and study of human EGC are lacking. EGC isolated from CD and control patients showed similar expression of glial markers and EGC-derived soluble factors (IL6, TGF-β, proEGF, GSH) but CD EGC failed to increase IEB resistance and healing. Lipid profiling showed that CD EGC produced decreased amounts of 15-HETE, 18-HEPE, 15dPGJ 2 and 11βPGF 2 α as compared to healthy EGC. They also had reduced expression of the L-PGDS and AKR1C3 enzymes. Produced by healthy EGC, the 11βPGF 2 activated PPARγ receptor of intestinal epithelial cells to induce cell spreading and IEB wound repair. In addition to this novel healing mechanism our data show that CD EGC presented impaired ability to promote IEB functions through defect in L-PGDS-AKR1C3-11βPGF 2 α dependent pathway.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep25203

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • 11-β-PGF2α is the principal immediate metabolic product of both PGD2 and PGE2.

    “11-β-PGF 2α is the principal immediate metabolic product of both PGD 2 and PGE 2 [72][73][74].”

    From Diagnosis of mast cell activation syndrome: a global "consensus-2" (2021) · cites this paper as [73]

    The Discussion (page not provided) calls 11βPGF2α the primary plasma metabolite of PGD2 and states that AKR1C3 converts PGD2 to 11βPGF2α. It does not identify 11βPGF2α as a metabolite of PGE2; its discussion of PGE2 concerns glial production and neuronal responses. (LLM, conf=0.89)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 73 · Cited by 48

Research works printed but not linked: 68

  1. Arrieta M. C., Bistritz L. & Meddings J. B. Alterations in intestinal permeability. Gut 55, 1512– 1520 (2006). 16966705 PMC1856434
  2. Coskun M. Intestinal epithelium in inflammatory bowel disease. Front Med (Lausanne) 1, 24 (2014). 25593900 PMC4292184
  3. Baert F. et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology 138, 463– 468; quiz e410– 461 (2010). 19818785
  4. Froslie K. F., Jahnsen J., Moum B. A. & Vatn M. H. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 133, 412– 422 (2007). 17681162
  5. Fischer A. et al. Adalimumab prevents barrier dysfunction and antagonizes distinct effects of TNF-alpha on tight junction proteins and signaling pathways in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 304, G970– 979 (2013). 23538493
  6. Neunlist M. et al. The digestive neuronal-glial-epithelial unit: a new actor in gut health and disease. Nat Rev Gastroenterol Hepatol 10, 90– 100 (2013). 23165236
  7. Furness J. B. The enteric nervous system and neurogastroenterology. Nat Rev Gastroenterol Hepatol 9, 286– 294 (2012). 22392290
  8. Hoff S. et al. Quantitative assessment of glial cells in the human and guinea pig enteric nervous system with an anti-Sox8/9/10 antibody. J Comp Neurol 509, 356– 371 (2008). 18512230
  9. Ferri G. L. et al. Evidence for the presence of S-100 protein in the glial component of the human enteric nervous system. Nature 297, 409– 410 (1982). 7043279
  10. Gabella G. Glial cells in the myenteric plexus. Z Naturforsch B 26, 244– 245 (1971). 4396549
  11. Ruhl A., Nasser Y. & Sharkey K. A. Enteric glia. Neurogastroenterol Motil 16 Suppl 1, 44– 49 (2004). 15066004
  12. Savidge T. C. MIND the gap: an astroglial perspective on barrier regulation. Neuron Glia Biol 3, 191– 197 (2007). 18634610
  13. Neunlist M. et al. Enteric glial cells: recent developments and future directions. Gastroenterology 147, 1230– 1237 (2014). 25305504
  14. Sharkey K. A. Emerging roles for enteric glia in gastrointestinal disorders. J Clin Invest 125, 918– 925 (2015). 25689252 PMC4362226
  15. Bach-Ngohou K. et al. Enteric glia modulate epithelial cell proliferation and differentiation through 15-deoxy-12,14-prostaglandin J2. J Physiol 588, 2533– 2544 (2010). 20478974 PMC2916986
  16. Neunlist M. et al. Enteric glia inhibit intestinal epithelial cell proliferation partly through a TGF-beta1-dependent pathway. Am J Physiol Gastrointest Liver Physiol 292, G231– 241 (2007). 16423922
  17. Van Landeghem L. et al. Enteric glia promote intestinal mucosal healing via activation of focal adhesion kinase and release of proEGF. Am J Physiol Gastrointest Liver Physiol 300, G976– 987 (2011). 21350188 PMC3119120
  18. Savidge T. C. et al. Enteric glia regulate intestinal barrier function and inflammation via release of S-nitrosoglutathione. Gastroenterology 132, 1344– 1358 (2007). 17408650
  19. Aube A. C. et al. Changes in enteric neurone phenotype and intestinal functions in a transgenic mouse model of enteric glia disruption. Gut 55, 630– 637 (2006). 16236773 PMC1856141
  20. Bush T. G. et al. Fulminant jejuno-ileitis following ablation of enteric glia in adult transgenic mice. Cell 93, 189– 201 (1998). 9568712
  21. Cornet A. et al. Enterocolitis induced by autoimmune targeting of enteric glial cells: a possible mechanism in Crohn’s disease? Proc Natl Acad Sci USA 98, 13306– 13311 (2001). 11687633 PMC60866
  22. Villanacci V. et al. Enteric nervous system abnormalities in inflammatory bowel diseases. Neurogastroenterol Motil 20, 1009– 1016 (2008). 18492026
  23. von Boyen G. B. et al. Distribution of enteric glia and GDNF during gut inflammation. BMC Gastroenterol 11, 3 (2011). 21235736 PMC3034687
  24. Pochard C. et al. Defects in 15-HETE Production and Control of Epithelial Permeability by Human Enteric Glial Cells from Patients With Crohn’s disease. Gastroenterology (2015). 26433161
  25. Soret R. et al. Characterization of human, mouse, and rat cultures of enteric glial cells and their effect on intestinal epithelial cells. Neurogastroenterol Motil 25, e755– 764 (2013). 23991747
  26. Martin-Venegas R., Roig-Perez S., Ferrer R. & Moreno J. J. Arachidonic acid cascade and epithelial barrier function during Caco-2 cell differentiation. J Lipid Res 47, 1416– 1423 (2006). 16585783
  27. Desmond J. C. et al. The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs. Cancer Res 63, 505– 512 (2003). 12543809
  28. Murakami M., Ohta T., Otsuguro K. I. & Ito S. Involvement of prostaglandin E(2) derived from enteric glial cells in the action of bradykinin in cultured rat myenteric neurons. Neuroscience 145, 642– 653 (2007). 17275193
  29. Blanco A., Alvarez S., Fresno M. & Munoz-Fernandez M. A. Amyloid-beta induces cyclooxygenase-2 and PGE2 release in human astrocytes in NF-kappa B dependent manner. J Alzheimers Dis 22, 493– 505 (2010). 20847443
  30. Takayama F. et al. Possible involvement of aiPLA2 in the phosphatidylserine-containing liposomes induced production of PGE2 and PGD2 in microglia. J Neuroimmunol 262, 121– 124 (2013). 23850486
  31. Xia M. & Zhu Y. Signaling pathways of ATP-induced PGE2 release in spinal cord astrocytes are EGFR transactivation-dependent. Glia 59, 664– 674 (2011). 21294165
  32. Abdo H. et al. The omega-6 fatty acid derivative 15-deoxy-Delta(1)(2),(1)(4)-prostaglandin J2 is involved in neuroprotection by enteric glial cells against oxidative stress. J Physiol 590, 2739– 2750 (2012). 22473776 PMC3424728
  33. Nicholson J. D. et al. PGJ(2) provides prolonged CNS stroke protection by reducing white matter edema. PLos One 7, e50021 (2012). 23284631 PMC3527449
  34. Lin T. N. et al. 15d-prostaglandin J2 protects brain from ischemia-reperfusion injury. Arterioscler Thromb Vasc Biol 26, 481– 487 (2006). 16385084
  35. Fernandez-Bustamante A. et al. Early increase in alveolar macrophage prostaglandin 15d-PGJ2 precedes neutrophil recruitment into lungs of cytokine-insufflated rats. Inflammation 36, 1030– 1040 (2013). 23616184
  36. Balestra B. et al. Colonic mucosal mediators from patients with irritable bowel syndrome excite enteric cholinergic motor neurons. Neurogastroenterol Motil 24, 1118– e1570 (2012). 22937879
  37. Heredia D. J., Grainger N., McCann C. J. & Smith T. K. Insights from a novel model of slow-transit constipation generated by partial outlet obstruction in the murine large intestine. Am J Physiol Gastrointest Liver Physiol 303, G1004– 1016 (2012). 22961801 PMC3517665
  38. Liston T. E. & Roberts L. J. 2nd Transformation of prostaglandin D2 to 9 alpha, 11 beta-(15S)-trihydroxyprosta-(5Z,13E)-dien-1-oic acid (9 alpha, 11 beta-prostaglandin F2): a unique biologically active prostaglandin produced enzymatically in vivo in humans. Proc Natl Acad Sci USA 82, 6030– 6034 (1985). 3862115 PMC390693
  39. Pugliese G., Spokas E. G., Marcinkiewicz E. & Wong P. Y. Hepatic transformation of prostaglandin D2 to a new prostanoid, 9 alpha,11 beta-prostaglandin F2, that inhibits platelet aggregation and constricts blood vessels. J Biol Chem 260, 14621– 14625 (1985). 3863819
  40. Coleman R. A. & Sheldrick R. L. Prostanoid-induced contraction of human bronchial smooth muscle is mediated by TP-receptors. Br J Pharmacol 96, 688– 692 (1989). 2720298 PMC1854400
  41. Lepak N. M. & Serrero G. Inhibition of adipose differentiation by 9 alpha, 11 beta-prostaglandin F2 alpha. Prostaglandins 46, 511– 517 (1993). 8295981
  42. Wang S., Yang Q., Fung K. M. & Lin H. K. AKR1C2 and AKR1C3 mediated prostaglandin D2 metabolism augments the PI3K/Akt proliferative signaling pathway in human prostate cancer cells. Mol Cell Endocrinol 289, 60– 66 (2008). 18508192
  43. Su W. et al. Differential expression, distribution, and function of PPAR-gamma in the proximal and distal colon. Physiol Genomics 30, 342– 353 (2007). 17519361
  44. Kato M. et al. Induction of differentiation and peroxisome proliferator-activated receptor gamma expression in colon cancer cell lines by troglitazone. J Cancer Res Clin Oncol 130, 73– 79 (2004). 14634802 PMC12161816
  45. Sarraf P. et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 4, 1046– 1052 (1998). 9734398
  46. Cloutier A. et al. The prostanoid 15-deoxy-Delta12,14-prostaglandin-j2 reduces lung inflammation and protects mice against lethal influenza infection. J Infect Dis 205, 621– 630 (2012). 22219346
  47. Ma C. et al. Key role of 15-lipoxygenase/15-hydroxyeicosatetraenoic acid in pulmonary vascular remodeling and vascular angiogenesis associated with hypoxic pulmonary hypertension. Hypertension 58, 679– 688 (2011). 21859965
  48. Potula H. S. et al. Src-dependent STAT-3-mediated expression of monocyte chemoattractant protein-1 is required for 15(S)-hydroxyeicosatetraenoic acid-induced vascular smooth muscle cell migration. J Biol Chem 284, 31142– 31155 (2009). 19736311 PMC2781513
  49. Soumya S. J. et al. Effect of 15-lipoxygenase metabolites on angiogenesis: 15(S)-HPETE is angiostatic and 15(S)-HETE is angiogenic. Inflamm Res 61, 707– 718 (2012). 22450700
  50. Vijil C., Hermansson C., Jeppsson A., Bergstrom G. & Hulten L. M. Arachidonate 15-lipoxygenase enzyme products increase platelet aggregation and thrombin generation. PLos One 9, e88546 (2014). 24533104 PMC3922896
  51. Yuan D. et al. Enhancement of the HIF-1alpha/15-LO/15-HETE axis promotes hypoxia-induced endothelial proliferation in preeclamptic pregnancy. PLos One 9, e96510 (2014). 24796548 PMC4010521
  52. Zhang L. et al. Platelet-derived growth factor (PDGF) induces pulmonary vascular remodeling through 15-LO/15-HETE pathway under hypoxic condition. Cell Signal 24, 1931– 1939 (2012). 22735810
  53. Cabral M., Martin-Venegas R. & Moreno J. J. Role of arachidonic acid metabolites on the control of non-differentiated intestinal epithelial cell growth. Int J Biochem Cell Biol 45, 1620– 1628 (2013). 23685077
  54. Ohata A., Usami M. & Miyoshi M. Short-chain fatty acids alter tight junction permeability in intestinal monolayer cells via lipoxygenase activation. Nutrition 21, 838– 847 (2005). 15975492
  55. Gobbetti T. et al. Polyunsaturated fatty acid metabolism signature in ischemia differs from reperfusion in mouse intestine. PLos One 8, e75581 (2013). 24073272 PMC3779198
  56. Bassotti G. et al. Enteric neuroglial apoptosis in inflammatory bowel diseases. J Crohns Colitis 3, 264– 270 (2009). 21172285
  57. Boisse L., Chisholm S. P., Lukewich M. K. & Lomax A. E. Clinical and experimental evidence of sympathetic neural dysfunction during inflammatory bowel disease. Clin Exp Pharmacol Physiol 36, 1026– 1033 (2009). 19566829
  58. Williams C. S. et al. MTG16 contributes to colonic epithelial integrity in experimental colitis. Gut 62, 1446– 1455 (2013). 22833394 PMC3663894
  59. Hokari R. et al. Increased expression and cellular localization of lipocalin-type prostaglandin D synthase in Helicobacter pylori-induced gastritis. J Pathol 219, 417– 426 (2009). 19768745
  60. Park J. M. et al. Hematopoietic prostaglandin D synthase suppresses intestinal adenomas in ApcMin/+ mice. Cancer Res 67, 881– 889 (2007). 17283118
  61. Zhong T., Xu F., Xu J., Liu L. & Chen Y. Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN Loss. Biomed Pharmacother 69, 317– 325 (2015). 25661377
  62. Yu Y. B. & Li Y. Q. Enteric glial cells and their role in the intestinal epithelial barrier. World J Gastroenterol 20, 11273– 11280 (2014). 25170211 PMC4145765
  63. Boesmans W. et al. Imaging neuron-glia interactions in the enteric nervous system. Front Cell Neurosci 7, 183 (2013). 24155689 PMC3801083
  64. Gulbransen B. D. & Sharkey K. A. Novel functional roles for enteric glia in the gastrointestinal tract. Nat Rev Gastroenterol Hepatol (2012). 22890111
  65. Bohorquez D. V. & Liddle R. A. The gut connectome: making sense of what you eat. J Clin Invest 125, 888– 890 (2015). 25729849 PMC4382222
  66. Bohorquez D. V. et al. An enteroendocrine cell-enteric glia connection revealed by 3D electron microscopy. PLos One 9, e89881 (2014). 24587096 PMC3935946
  67. Geboes K. et al. Major histocompatibility class II expression on the small intestinal nervous system in Crohn’s disease. Gastroenterology 103, 439– 447 (1992). 1378803
  68. Le Faouder P. et al. LC-MS/MS method for rapid and concomitant quantification of pro-inflammatory and pro-resolving polyunsaturated fatty acid metabolites. J Chromatogr B Analyt Technol Biomed Life Sci 932, 123– 133 (2013). 23831705

Authors
Coquenlorge, S., Van Landeghem, L., Jaulin, J., Cenac, N., Vergnolle, N., Duchalais, E., Neunlist, M., & Rolli-Derkinderen, M.
Affiliations
  • Inserm (FR)
  • Centre National de la Recherche Scientifique (FR)
ORCID
Venue
Scientific Reports
Publisher
Springer Science and Business Media LLC
Published
2016-05-03
Volume
6
Issue
1
Pages
25203-25203
ISSN
2045-2322 (ISSN-L)
DOI
10.1038/srep25203
PMC
PMC4853710
OpenAlex
W2345694465
Cited by
48
References
73
Citations by year
2026: 3 · 2025: 4 · 2024: 5 · 2023: 8 · 2022: 5 · 2021: 6 · 2020: 6 · 2019: 3 · 2018: 6 · 2017: 1 · 2016: 1
FWCI
2.96
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
Funders
  • Institut National de la Santé et de la Recherche Médicale
  • Ligue Contre le Cancer
  • Centre National de la Recherche Scientifique
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Inflammatory Bowel Disease
  • Health Sciences › Medicine › Pharmacology › Inflammatory mediators and NSAID effects
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Keywords
arachidonic acid metabolites, enteric glial cells, intestinal epithelial barrier, Crohn's disease, lipidomics, 15-hydroxyeicosatetraenoic acid, lipocalin-type prostaglandin D synthase, AKR1C3, PPARγ, wound healing
MeSH terms
Aldo-Keto Reductase Family 1 Member C3, Adolescent, Adult, Aged, Aged, 80 and over, Cells, Cultured, Crohn Disease, Epithelial Cells, Female, Humans, Hydroxyeicosatetraenoic Acids, Intestinal Mucosa, Intestines, Male, Middle Aged, Wound Healing, Eicosapentaenoic Acid, Prostaglandin D2, Dinoprost, Coculture Techniques, Caco-2 Cells, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review